Because appetite is naturally reduced and individuals feel full faster, the quality of the food consumed becomes exceptionally important
The addition of B12 gives the serum a distinctive pink color, making it easily distinguishable from other medications
Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes
The meal planning resources and food guides for GLP-1 therapy provide frameworks that apply across the entire class
At 12 months, the on-medication MDS-UPDRS Part III score was 14.9 in the lixisenatide group versus 18.8 in the placebo group, a between-group difference of 3.08 points (P = 0.007) [3]
Find out at Obesity: A Worldwide Pandemic with Advancing Management Options . Novo Nordisk: The Pioneer in GLP-1 Therapy Novo Nordisk, the pharmaceutical giant, revolutionized weight loss treatment by pioneering GLP-1 receptor agonists